Breast Cancer Coverage from Every Angle

Jennifer K. Litton, MD, on BRCA-Mutated Breast Cancer, Changing the Standard of Care, and Treatment Sequencing

Posted: Tuesday, May 26, 2020

Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, talks about the strides made with antibody-drug conjugates for treatment of BRCA-mutated disease, improvement in quality of life, and the possibility that administering PARP inhibitors first can make immunotherapy more effective.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.